

Resource Summary Report

Generated by PRECISE-TBI on Sep 18, 2026

Phospho-Stat3 (Ser727) Antibody

RRID:AB_331589

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9134, RRID:AB_331589

Antibody Information

URL: http://antibodyregistry.org/AB_331589

Proper Citation: Cell Signaling Technology Cat# 9134, RRID:AB_331589

Target Antigen: Phospho-Stat3 (Ser727)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, ChIP. Consolidation on 10/2018: AB_10078146, AB_10828368, AB_331589, AB_331590.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Stat3 (Ser727) Antibody

Description: This polyclonal targets Phospho-Stat3 (Ser727)

Target Organism: b, dg, rat, hm, hamster, h, porcine, hr, canine, m, horse, mouse, r, pg, bovine, human, mk

Antibody ID: AB_331589

Vendor: Cell Signaling Technology

Catalog Number: 9134

Record Creation Time: 20231110T064643+0000

Record Last Update: 20260829T073054+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Stat3 (Ser727) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 64 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Aksu AM, et al. (2026) JNK1 mediates serine phosphorylation of STAT3 in response to fatty acids released by lipolysis. Journal of lipid research, 67(3), 100991.

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. International journal of molecular sciences, 27(4).

Liu J, et al. (2026) ERK1/2 hijack STAT3 via Thr714 phosphorylation to suppress gene expression. Cell communication and signaling : CCS, 24(1).

Yang D, et al. (2026) Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing ROR γ t and suppressing glucocorticoid receptor activity. Immunity.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. Cell reports, 45(6), 117427.

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. Cancer discovery, 16(3), 497.

da Silva RAG, et al. (2026) Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. Cell host & microbe, 34(2), 245.

Kadam R, et al. (2026) Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1. Cell reports, 45(4), 117263.

Chen H, et al. (2025) DAP12 deletion reduces neuronal SLIT2 and demyelination and enhances brain resilience in female tauopathy mice. *Molecular neurodegeneration*, 20(1), 124.

Bernal S, et al. (2025) Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease. *Redox biology*, 84, 103670.

Zhu YP, et al. (2025) TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice. *Acta pharmacologica Sinica*.

Yang L, et al. (2025) Hepatocyte metabolic adaptations during pregnancy and lactation. *Cell*.

Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. *Cell reports*, 44(5), 115676.

Desmarais F, et al. (2025) A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(20), e71172.

Bancet A, et al. (2024) Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric γ D pocket. *iScience*, 27(2), 108903.

Zarco N, et al. (2024) Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. *iScience*, 27(12), 111311.

Tang GX, et al. (2024) Mitochondrial RelA empowers mtDNA G-quadruplex formation for hypoxia adaptation in cancer cells. *Cell chemical biology*, 31(10), 1800.

Zhang K, et al. (2024) VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. *Cell reports*, 43(1), 113661.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8⁺ T cells. *Cell*, 187(9), 2288.